| Literature DB >> 34336991 |
Huda Mossa Omran1,2, Moiz Bakhiet1, Volker Ehemann3.
Abstract
The effect of sperm molecular defects on fertilization and pregnancy outcome after assisted reproductive therapy (ART) is widely documented by both research and clinical societies. Sperm DNA fragmentation and abnormal chromatin condensation represent critical causes of male infertility. Advanced androgenic techniques for accurately identifying molecular defects help in selecting an appropriate treatment strategy. Additionally, specific markers of apoptosis are increasingly important in predicting male infertility. The ability of flow cytometry to estimate the quantity of sperm with DNA fragmentation or damage and multifactor measurements in immotile sperm have made this developed technique essential in fertility centers. The study is aimed at assessing the level of DNA fragmentation and apoptosis by measuring flow cytometry using new techniques. Flow cytometry analysis revealed a varying degree of DNA damage. It was able to quantify the degree of impairment even in samples with minimal DNA fragmentation. DNA damage was observed even in samples that were considered normal with a routine semen analysis. Flow cytometry was sensitive to changes in sperm apoptosis. Elevated p53 activity levels were associated with high DNA fragmentation. Meanwhile, B-cell lymphoma 2 (Bcl-2) activities showed a different pattern. In conclusion, flow cytometry for sperm DNA fragmentation and markers of apoptosis can be a valuable tool in assisted reproductive centers.Entities:
Year: 2021 PMID: 34336991 PMCID: PMC8313342 DOI: 10.1155/2021/9531775
Source DB: PubMed Journal: Int J Reprod Med ISSN: 2314-5757
Values of standard parameters of normal and abnormal samples by WHO∗ analysis.
| Parameter | Normal (mean ± 2SD) | Abnormal (mean ± 2SD) |
|---|---|---|
| Concentration (×106/ml) | 83.18 ± 9.93 | 23.73 ± 5.34 |
| Motility (% grade a) | 6 0.18 ± 1.96 | 33.70 ± 3.96 |
| Vitality (% alive) | 68.37.84 ± 2.42 | 47.73 ± 4.56 |
| Morphology (% normal form) | 9.83 ± 0.68 | 3.46 ± 0.70 |
| Leukocyte count (×106/ml) | 0.85 ± 0.15 | 1.23 ± 0.27 |
WHO: World Health Organization.
Figure 1Cytometry result of p53 labeled samples: (a) normal sample with 0.16% of positively labeled cells; (b) abnormal sample with 6.55% of positively labeled cells.
Figure 2Cytometry result of Bcl-2-FITC labeled samples: (a) normal sample with 0.9% of positively labeled cells; (b) abnormal sample with 13.3% of positively labeled cells.
Figure 3Distributions of patients according to cytometry classes vs. Bcl-2 activity.
Figure 4Distributions of patients according to cytometry classes vs. p53 activity.
Figure 5Cytometry result of sample 11: (a) normal chromatin condensation sample with normal p53 activity (0.16% of positively labeled cells); (b) abnormal Bcl-2 activity of the same sample with 13.3% of positively labeled cells.